Hemolytic-Uremic Syndrome, Atypical
Also known as: Atypical Hemolytic Uremic Syndrome(aHUS) / AHUS / AHUS - Atypical Hemolytic Uremic Syndrome / Atypical Hemolytic Uraemic Syndrome / Atypical Hemolytic-Uremic Syndrome / Atypical Hemolytic Uremic Syndrome (aHUS) / Atypical Hemolytic Uremic Syndrome / Hemolytic Uremic Syndrome, Atypical / Atypical hemolytic uremic syndrome (disorder) / Atypical haemolytic uraemic syndrome
Drug | Drug Name | Drug Description |
---|---|---|
DB01257 | Eculizumab | A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). |
DB11580 | Ravulizumab | A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB01257 | Eculizumab | Complement C5 | target |
DB11580 | Ravulizumab | Complement C5 | target |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB15011 | Avacopan | 2 | Terminated | 1 |
DB16121 | Cemdisiran | 2 | Withdrawn | 2 |
DB01257 | Eculizumab | 2 | Completed | 8 |
DB01257 | Eculizumab | 2 | Terminated | 1 |
DB16128 | Crovalimab | 3 | Recruiting | 2 |
DB01257 | Eculizumab | 3 | Active Not Recruiting | 1 |
DB16200 | Iptacopan | 3 | Not Yet Recruiting | 1 |
DB16200 | Iptacopan | 3 | Recruiting | 2 |
DB16418 | Narsoplimab | 3 | Unknown Status | 1 |
DB11580 | Ravulizumab | 3 | Completed | 2 |
DB01257 | Eculizumab | 4 | Completed | 1 |
DB01257 | Eculizumab | Not Available | Completed | 1 |